



Friday, 14 November

08.15-08.25 Welcome and Introduction

ESMO J. Bellmunt, Barcelona (ES)
ESTRO P. Poortmans, Tilburg (NL)
EAU P-A. Abrahamsson, Malmö (SE)
ESUR G. Heinz-Peer, Saint Poelten (AT)
ESP/ESUP A. Lopez-Beltran, Lisbon (PT)

08.25-10.45 Prostate cancer: Management of progressing disease

Chairs: Urologist A. Bjartell, Malmö (SE)
Urologist G. Giannarini, Udine (IT)
Clinical oncologist V. Khoo, London (GB)

08.25-08.35 Case presentation including voting

Urologist – G. Giannarini, Udine (IT)

08.35-08.50 Optimising imaging for biochemical recurrence

Radiologist – J. Barentsz, Nijmegen (NL)

08.50-09.10 Understanding the natural history of progressing PCa: Is treatment always needed?

Urologist – M. Gleave, Vancouver (CA)

09.10-09.30 Intermittent hormonal therapy - for the worse or the better?

Medical oncologist – M. Hussain, Michigan (US)

09.30-09.40 Intermittent hormonal therapy - for the better or the worse?

Urologist - P-A. Abrahamsson, Malmö (SE)

09.40-09.50 Discussion

09.50-10.05 Curative radiotherapy for local recurrence: When and to whom?

Radiation oncologist – M. Van Vulpen, Utrecht (NL)

10.05-10.20 Curative surgery for local recurrence: When and to whom?

Urologist – S. Joniau, Leuven (BE)

10.20-10.35 Optimal treatment sequencing for mCRPC: When is docetaxel (not) the first choice?

Medical oncologist – G. Attard, Sutton (GB)

10.35-10.45 Discussion and conclusions from the chairmen

10.45-11.15 Coffee break and poster viewing

11.15-11.30 Best of journals: Medical oncology

Chairs: Clinical oncologist A. Horwich, Sutton (GB)
Medical oncologist S. Osanto, Leiden (NL)

11.30-12.15 Debate: Is surveillance the standard of care for all stage 1 testicular cancers?

Chairs: Oncologist G. Daugaard, Copenhagen (DK)
Urologist M. Jewett, Toronto (CA)

11.30-11.45 Pro

Urologist – N. Mottet, Saint Etienne (FR)

11.45-12.00 Con

Medical oncologist – J. Oldenburg, Oslo (NO)

12.00-12.15 Discussion and conclusions from the chairmen

12.15-12.35 Translational research session: When science meets the clinic

Chair: Medical oncologist – C. Sternberg, Rome (IT)

The role of checkpoint inhibitors in Uro-Oncology

Medical oncologist – J. Bellmunt, Boston (US)

12.35-13.35 Lunch and poster viewing & symposium

- 13.35-15.15 General session: Kidney cancer - Locally advanced**
Chairs: Urologist S. Brookman-May, Munich (DE)
Oncologist T. Eisen, Cambridge (GB)
Urologist P. Mulders, Nijmegen (NL)
- 13.35-13.55 Do we need more than CT for staging and follow up?**
Radiologist – P. Fries, Homburg (DE)
- 13.55-14.15 Defining the optimal extent of surgery: The role of lymph node dissection**
Urologist – M. Blute, Boston (US)
- 14.15-14.35 Genomics will determine the management of locally advanced RCC**
Medical oncologist – J. Brugarolas, Dallas (US)
- 14.35-14.55 Drugs in the pipeline for RCC**
Medical oncologist – B. Escudier, Villejuif (FR)
- 14.55-15.15 Discussion and conclusions from the chairmen**
- 15.15-15.45 Coffee break and poster viewing**
- 15.45-17.25 Bladder cancer**
Chairs: Medical oncologist J. Bellmunt, Boston (US)
Urologist M. Brausi, Modena (IT)
Radiation oncologist B. Jereczek-Fossa, Milan (IT)
- 15.45-16.05 Imaging approaches in bladder cancer: Can we do better?**
Radiologist – G. Heinz-Peer, Saint Poelten (AT)
- 16.05-16.25 The role of minimally invasive radical cystectomy**
Urologist – C.M. Annerstedt, Stockholm (SE)
- 16.25-16.45 Bladder preserving strategies: When and how?**
Oncologist – R. Huddart, Sutton (GB)
- 16.45-17.05 Translational approach to the management of bladder cancer**
Urological researcher – T. Orntoft, Aarhus (DK)
- 17.05-17.25 Discussion and conclusions from the chairmen**
- 17.30-18.30 Symposium**

Saturday, 15 November

08.30-09.10 Oral presentations of the best abstracts

Chairs: Urologist F. Chun, Hamburg (DE)
Clinical oncologist V. Khoo, London (GB)
Medical oncologist S. Osanto, Leiden (NL)

O1 Chromosome X polysomy is associated with increased androgen receptor expression in epithelial cells and reduced expression in stromal cells in treatment-naïve prostate cancer

C. Van Praet, F. Poelaert, S. Verschuere, L. Libbrecht, M. Praet, S. Rottey, S. Van Belle, K. Decaestecker, T. Claeys, N. Lumen (Ghent, Belgium)

O2 Results of EORTC 22991: 3D-CRT/IMRT with or without 6-month androgen deprivation therapy in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991)

M. Bolla, P. Maingon, A. Van Den Bergh, C. Carrie, S. Villa, P. Kitsios, P. Poortmans, S. Sundar, E. Van Der Steen-Banasik, L. Collette, EORTC Radiation Oncology Group (Grenoble, Dijon, Lyon, France; Groningen, Tilburg, Arnhem, The Netherlands; Badalona, Spain; Nicosia, Cyprus; Nottingham, United Kingdom; Brussels, Belgium)

O3 Bone scan index as a biomarker to predict outcome in mCRPC patients on abiraterone acetate (Zytiga™) – a multicenter study

M. Reza, A. Bjartell, M. Ohlsson, R. Kaboteh, I. Frank, J.-E. Damber, L. Budäus, T. Eichenauer, P. Wollmer, L. Edenbrandt, E. Trägårdh (Malmö, Lund, Gothenburg, Sweden; Hamburg, Germany)

O4 The long term outcome of combined NBI-plasma vaporization approach in large NMIBT cases – a prospective, randomized controlled comparison to the standard management

B. Geavlete, R. Multescu, D. Georgescu, C. Moldoveanu, F. Stanescu, M. Jecu, P. Geavlete (Bucharest, Romania)

O5 Patients with metastatic papillary Renal Cell Carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database

D. Keizman, M. Gottfried, N. Maimon, H. Hammers, M. Eisenberger, M. Carducci, V. Sinibaldi, V. Neiman, E. Rosenbaum, D. Sarid, E. Gez, A. Peer, A. Sella, W. Mermershtain, K. Rouvinov, R. Berger, J. Lee (Kefar-saba, Petach Tikva, Tel-Aviv, Haifa, Zerifin, Beer-Sheva, Tel-Hashomer, Israel; Baltimore, United States of America; Seoul, South Korea)

09.10-09.20 Announcement best unmoderated posters

Moderator: Radiation oncologist – M. Van Vulpen, Utrecht (NL)

09.20-09.40 Lecture: The role of stem cells across tumour types

Chair: Medical oncologist – J. Bellmunt, Boston (US)
Speaker: Molecular genetician – N. Maitland, York (GB)

Parallel session

09.20-11.20 Hands on Training (HOT) Prostate radiotherapy delineation contouring workshop

Chair: C. Salembier, Brussels (BE)
Panellists: V. Khoo, London (GB)
M. Van Vulpen, Utrecht (NL)
Administrator: B. De Bari, Lausanne (CH)

09.40-11.20 Kidney cancer: Management of small renal masses

Chairs: Pathologist A. Lopez-Beltran, Lisbon (PT)
Urologist M. Blute, Boston (US)
Urologist J. Walz, Marseille (FR)

- 09.40-09.50 **Case presentation including voting**
Urologist – J. Walz, Marseille (FR)
- 09.50-10.05 **Role of imaging in predicting histology of small renal masses**
Radiologist – H. Thoeny, Berne (CH)
- 10.05-10.20 **Role of percutaneous renal biopsy: Why, when and how**
Urologist – A. Volpe, Novara (IT)
- 10.20-10.35 **Active surveillance is often applicable**
Urologist – M. Jewett, Toronto (CA)
- 10.35-10.50 **Role of focal treatments**
Urologist – M. Laguna, Amsterdam (NL)
- 10.50-11.05 **Is there a role for stereotactic or other methods of external beam radiotherapy?**
Radiation oncologist – G. De Meerleer, Ghent (BE)
- 11.05-11.20 Discussion and conclusions from the chairmen
- 11.20-11.50 *Coffee break and poster viewing***
- 11.50-12.05 Best of journals: Surgery**
Urologist C. Surcel, Bucharest (RO)
Urologist H. Van Poppel, Leuven (BE)
- 12.05-12.15 Late breaking news**
Chair: Medical oncologist – J. Bellmunt, Boston (US)
- Distinguishing favorable from non-favorable prostate cancer with novel prognostic proteomics prostate cancer biopsy test, ProMark™**
Urologist – M. Shipitsin, Cambridge (US)
- 12.15-13.05 Quality assessment in uro-oncology**
Chairs: Radiation oncologist M. Bolla, Grenoble (FR)
Urologist A. Briganti, Milan (IT)
Oncologist G. Daugaard, Copenhagen (DK)
- 12.15-12.25 **Surgery**
Urologist – F. Chun, Hamburg (DE)
- 12.25-12.35 **Radiation therapy**
Radiation oncologist – A. Bossi, Villejuif (FR)
- 12.35-12.45 **Medical treatment**
Medical oncologist – C. Sweeney, Boston (US)
- 12.45-12.55 **Imaging**
Radiologist – J. Futterer, Nijmegen (NL)
- 12.55-13.05 Discussion and conclusions from the chairmen
- 13.05-14.05 *Lunch and poster viewing & symposium***
- 14.05-14.25 Lecture: How to optimise screening in prostate cancer**
Epidemiologist's perspective:
Epidemiologist – S. Carlsson, New York (US)
- 14.25-14.35 Discussion led by:
Urologist - TBC
- 14.35-15.50 Prediction and prevention of treatment related toxicity in uro-oncology**
Chairs: Urologist W. Artibani, Verona (IT)
Radiation oncologist D. Dearnaley, Sutton (GB)
Medical oncologist S. Osanto, Leiden (NL)
- 14.35-14.55 **Surgery/ minimal invasive/ organ preserving**
Urologist - P. Gontero, Turin (IT)
- 14.55-15.15 **Radiation therapy**
Radiation oncologist – R. Valdagni, Milan (IT)
- 15.15-15.35 **Anticipative management of adverse effects in patients treated with systemic therapy**
Clinical oncologist – J. Oldenburg, Oslo (NO)
- 15.35-15.50 Discussion and conclusions from the chairmen
- 15.50-16.20 *Coffee break and poster viewing***

16.20-16.35 Best of journals: Radiotherapy
Radiation oncologist – M. Van Vulpen, Utrecht (NL)
Radiation oncologist – P. Poortmans, Tilburg (NL)

16.35-16.55 Late breaking news
Chair: Urologist - H. Van Poppel, Leuven (BE)

An overview of the 2nd conference on active surveillance for low risk prostate cancer, Amsterdam 2014
Urologist – M. Roobol, Rotterdam (NL)

16.55-17.55 Penile cancer
Chairs: Urologist H. Van Poppel, Leuven (BE)
Radiotherapist C. Haie-Meder, Villejuif (FR)

16.55-17.10 HPV and penile cancer
Pathologist – M. Colecchia, Milan (IT)

17.10-17.25 Imaging for staging and recurrence of penile cancer
Urologist – S. Minhas, London (GB)

17.25-17.40 Lymph node management in penile cancer
Urologist – S. Horenblas, Amsterdam (NL)

17.40-17.55 Discussion and conclusions from the chairmen

18.00-19.00 *Symposium*

Sunday, 16 November

- 09.00-09.20 Immunotherapy in prostate cancer**
Chair: Urologist – B. Tombal, Brussels (BE)
Speaker: Medical oncologist – K. Fizazi, Villejuif (FR)
- 09.20-09.30 Announcement best unmoderated posters**
Moderator: Urologist – H. Van Poppel, Leuven (BE)
- 09.30-10.00 Coffee break and poster viewing**
- 10.00-12.00 The really high-risk prostate cancer**
Chairs: Urologist N. Clarke, Manchester (GB)
Clinical oncologist V. Khoo, London (GB)
Urologist S. Joniau, Leuven (BE)
- 10.00-10.10 Case presentation including voting**
Radiation oncologist – V. Khoo, London (GB)
- 10.10-10.25 What is really high-risk prostate cancer? Role of biomarker and genetic assessment**
Urologist – R. Karnes, Rochester (US)
- 10.25-10.40 Is radiotherapy with hormone therapy still the gold standard?**
Urologist – O. Yossepowitch, Petah Tikva (IL)
- 10.40-10.55 Has radical prostatectomy proven to be the best primary treatment?**
Radiation oncologist – A. Bossi, Villejuif (FR)
- 10.55-11.10 Role of robotic assisted radical prostatectomy: A step forward?**
Urologist – F. Montorsi, Milan (IT)
- 11.10-11.25 Should primary cancer be treated in metastatic patients?**
Urologist – B. Tombal, Brussels (BE)
- 11.25-12.00 Discussion and conclusions from the chairmen**
- 12.00-12.45 Take home messages**
- 12.00-12.10 Urologist/Imaging J. Walz, Marseille (FR)
12.10-12.20 Urologist A. Briganti, Milan (IT)
12.20-12.30 Clinical oncologist V. Khoo, London (GB)
12.30-12.40 Radiation oncologist A. Bossi, Villejuif (FR)
12.40-12.45 Pathologist A. Lopez-Beltran, Lisbon (PT)
- 12.45-13.00 Closing remarks**
Urologist H. Van Poppel, Leuven (BE)
Medical oncologist S. Osanto, Leiden (NL)
Radiation oncologist P. Poortmans, Tilburg (NL)